Evidence map›Paper›PMID 41738259›Full record

ArticleClinical and experimental rheumatology2026

Recurrent and new primary cancer risk in adult patients with idiopathic inflammatory myositis and a history of malignancy.

Xingyao Wang, Jemima Albayda, Julie J Paik, Eleni Tiniakou, Brit L Adler, Andrew L Mammen, Livia Casciola-Rosen, Lisa Christopher-Stine, Christopher A Mecoli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xingyao WangDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jemima AlbaydaDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Julie J PaikDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Eleni TiniakouDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Brit L AdlerDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew L MammenDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD; and Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Livia Casciola-RosenDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD,USA.
Lisa Christopher-StineDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; and Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Christopher A MecoliDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. cmecoli1@jhmi.edu.

Funding

Sample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, Antony Rosen · 2016 to 2026
$8.9M
Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to CancerR01AR073208 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI LIVIA A CASCIOLA-ROSEN, Ami Aalok Shah · 2018 to 2026
$5.2M
Prediction and Significance of Cancer in Idiopathic Inflammatory MyositisR01AR083912 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Christopher Mecoli · 2024 to 2026
$1.6M
NIAMS NIH HHS P30 AR070254NIAMS NIH HHS R01 AR073208NIAMS NIH HHS R01 AR083912
6 · The paper itself

Abstract

objectivesIn adult patients with idiopathic inflammatory myopathies (IIM) and a history of cancer, the risk of subsequent cancer is unclear. We describe our centre's experience with recurrent and new primary cancer development after IIM symptom onset.

methodsA retrospective cohort study was conducted at The Johns Hopkins Myositis Center, analysing adult IIM patients enrolled from 2003 to 2024 with a documented cancer history. Patients were categorised into three groups: 1. remained cancer-free, 2. had cancer recurrence, or 3. developed a new primary cancer.

resultsAmong 2,476 IIM patients, 280 (11%) had a cancer history, with 39 (14%) diagnosed within the 3 years prior to IIM symptom onset. Of these, 29 (74%) remained cancer-free after symptom onset over a median follow-up period of 5.5 (IQR 6.7) years. Six patients (16%) experienced cancer recurrence, and four (10%) developed a new primary cancer after IIM symptom onset. The median time from index cancer to recurrence was 2.4 (IQR 1.6) years, whereas the time from index cancer to new primary was 1.4 (IQR 1.0) years. Of the ten patients who developed either recurrence or a new primary cancer after IIM symptom onset, all were diagnosed within the first three years after IIM symptom onset.

conclusionsIn our tertiary referral centre, approximately one quarter of adult IIM patients who had a cancer diagnosis in the three years before IIM onset went on to develop an additional malignancy, either a recurrence or a new primary.

Indexed as

MyositisNeoplasm Recurrence, LocalNeoplasmsAdultAgedFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsTime Factors

Identifiers

PMID41738259
PMCPMC12948041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.